
PharmaIN, a US-based biopharmaceutical firm, enhances injectable therapeutics via patented PGC™ technology.
PharmaIN, founded in Bothell, United States, is a development-stage biopharmaceutical company dedicated to enhancing injectable therapeutics through its proprietary Protected Graft Copolymer (PGC™) technology. This technology, licensed from Massachusetts General Hospital, aims to extend the half-life and improve the targeted delivery of proteins, peptides, siRNA, and potent small molecule therapeutics. PharmaIN's market focus includes addressing critical needs in drug delivery systems to improve patient outcomes.
Notable affiliations include Massachusetts General Hospital, from which PharmaIN licenses its core technology. Key achievements involve the development of investigational drug therapies like PHIN-214, although these have not yet received FDA approval. The company's impact lies in its innovative approach to drug delivery, potentially transforming therapeutic efficacy and patient care in the biopharmaceutical industry.

Pinpoint Pharma
pinpointpharma.co

PIN Pharma
pinpharma.com
pH Pharma
ph-pharma.com

Ziran Biopharmaceutical

BioQ Pharma
bioqpharma.com

InSitu Biologics

Prometheon Pharma

InpharmD
inpharmd.com

Trilogic Pharma
trilogicpharma.com

Pharmatrophix
pharmatrophix.com

Inipharm
inipharm.com

BiotechInnova
biotechinnova.com

iCeutica

Phoreus Biotechnology
phoreusbiotech.com
Protect Pharmaceutical
Companies similar to PharmaIN include Pinpoint Pharma, PIN Pharma, pH Pharma and Ziran Biopharmaceutical.
PharmaIN was founded in 2001.
PharmaIN's headquarters is located in Bothell, WA, US.
PharmaIN's most recent funding round was for $1.5M (USD) in May 2014.
As of May 16, 2014, PharmaIN has raised a total of $1.5M (USD).
PharmaIN has 18 employees as of Feb 4, 2024.